Scarica l'app Stockscreener
2.68
5.96%
-0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.85
Aprire:
$2.82
Volume 24 ore:
201.00K
Relative Volume:
2.66
Capitalizzazione di mercato:
$9.22M
Reddito:
$468.00K
Utile/perdita netta:
$-10.34M
Rapporto P/E:
-0.3801
EPS:
-7.05
Flusso di cassa netto:
$-8.94M
1 W Prestazione:
+36.04%
1M Prestazione:
+18.06%
6M Prestazione:
+12.13%
1 anno Prestazione:
-52.36%
Intervallo 1D:
$2.55
$3.17
Intervallo di 1 settimana:
$2.23
$3.20
Portata 52W:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Confronta BCDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.23 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 355.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2199 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.50 | 211.65M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.00 | 156.75M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia
Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance
BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus
BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus
Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa
BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com
Emory University joins phase III heart failure trial - Investing.com Australia
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener
BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com
BioCardia completes enrollment for heart therapy trial - MSN
Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):